Sionna Therapeutics Inc. Common Stock

SION· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$3.73-3.62%

2026-11-02

Financials

Valuation Metrics

Sionna Therapeutics Inc. Common Stock's Market Cap is $168M. At end of 2025 it was $1.64B. Ranked #3004 of 3,116 in US market (top 96%), #1378 of 1,472 on NASDAQ (top 94%), #249 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$168M	US#3,004/3,116 Sec#249/265
Revenue	$0.00	US#2,859/3,116 Sec#193/265
Net Income	$-97M	US—/3,116 Sec—/265
Total Assets	$283M	US#2,914/3,116 Sec#212/265
Net Assets	$266M	US#2,559/3,116 Sec#161/265
Employees	59	US#2,682/3,116 Sec#203/265
Value
P/B	0.63x	US#164/3,116 Sec#7/265
FCF Yield	-58.22%	US—/3,116 Sec—/265
Profitability
ROE	-36.64%	US#2,599/3,116 Sec#125/265
ROA	-34.38%	US#2,910/3,116 Sec#171/265
Financial Health
Debt Ratio	6.57%	US#59/3,116 Sec#29/265
Total Debt	$8M	US#2,849/3,116 Sec#205/265
FCF	$-98M	US#2,630/3,116 Sec#143/265
Cash	$63M	US#2,467/3,116 Sec#210/265
Current Ratio	20.05x	US#117/3,116 Sec#25/265
Performance
1Y Return	-90.24%	US#3,112/3,116 Sec#263/265
1M Return	-24.03%	US#2,924/3,116 Sec#237/265
From 52W High	-93.21%	US#3,116/3,116 Sec#263/265
1Y MDD	-92.95%	US#3,116/3,116 Sec#263/265
Trading
Volume	650,498 shares	US#1,958/3,116 Sec#196/265
Trading Value	$2M	US#2,852/3,116 Sec#235/265
Per Share
EPS	$-2.16	US—/3,116 Sec—/265
BPS	$5.89	US#2,198/3,116 Sec#112/265

Company Info

CEO Michael Cloonan

Employees 59

HQ Waltham, US

Website https://www.sionnatx.com

Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.